Who We Are

Nature continuously pushes the limits of biology, yet these phenomenal outcomes rarely make their way to patients. At Peel Therapeutics, we are determined to change that.  

​

We are an evolutionary-inspired, clinical-stage biotech company developing medicines to transform patients’ lives. Peel (the Hebrew word for “elephant”) launched with a focus on cancer-fighting proteins in elephants and quickly recognized the power of using evolution's solutions to treat and prevent disease. In addition to developing elephant p53 (EP53) nanoparticles for the treatment of cancer, our team is advancing additional therapies derived from nature’s super-abilities to treat a number of diseases.  

Our Approach

Life science R&D has produced countless new therapies with positive health outcomes, but it cannot compare to ages of evolutionary history. We seek out distinct proteins and molecules in nature that have exceeded what we thought was biologically possible. We then apply our expertise and technology to rapidly translate this evolutionary biology and advance our therapeutic pipeline to treat a spectrum of devastating conditions, including cancer and inflammation.  

Our Leadership

Our multidisciplinary team across the US and Israel offers a unique blend of scientific and medical expertise, enthusiasm and curiosity. We hail from all corners of academia and clinical medicine, and the patients we serve are the driving force behind the work we do every day.